This HTML5 document contains 42 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01278/identifier/pharmgkb/
n18http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n22http://linked.opendata.cz/resource/drugbank/dosage/
n20http://linked.opendata.cz/resource/drugbank/drug/DB01278/identifier/kegg-drug/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01278/identifier/drugbank/
n17http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n23http://linked.opendata.cz/resource/drugbank/drug/DB01278/identifier/national-drug-code-directory/
n5http://www.rxlist.com/cgi/generic/
n7http://linked.opendata.cz/resource/drugbank/patent/
n9http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n6http://www.drugs.com/cdi/
n21http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/ontology/sukl/drug/
n15http://linked.opendata.cz/resource/atc/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01278/identifier/wikipedia/

Statements

Subject Item
n2:DB01278
rdf:type
n3:Drug
n3:description
Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes.
n3:dosage
n22:271B628E-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Jones MC: Therapies for diabetes: pramlintide and exenatide. Am Fam Physician. 2007 Jun 15;75(12):1831-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17619527 # Ryan GJ, Jobe LJ, Martin R: Pramlintide in the treatment of type 1 and type 2 diabetes mellitus. Clin Ther. 2005 Oct;27(10):1500-12. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16330288 # Edelman S, Maier H, Wilhelm K: Pramlintide in the treatment of diabetes mellitus. BioDrugs. 2008;22(6):375-86. doi: 10.2165/0063030-200822060-00004. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18998755 # Kleppinger EL, Vivian EM: Pramlintide for the treatment of diabetes mellitus. Ann Pharmacother. 2003 Jul-Aug;37(7-8):1082-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12841822
n3:group
investigational approved
n3:halfLife
Approximately 48 minutes
n3:indication
For the treatment of type 1 and type 2 diabetes mellitus as an adjunct to preprandial insulin therapy in patients without adequate glycemic control of insulin therapy.
owl:sameAs
n9:DB01278 n17:DB01278
dcterms:title
Pramlintide
adms:identifier
n12:PA164781394 n13:Pramlintide n19:DB01278 n20:D05595 n23:66780-115-02
n3:mechanismOfAction
Pramlintide is an amlyinomimetic, a functional analog of the naturally occurring pancreatic hormone amylin. Amylin has activity in a number of gastrointestinal and glucodynamic systems, and by mimicking its activity, pramlintide acts to improve glycemic control through modulation of the rate of gastric emptying, prevention of post-prandial rise in glucagon levels, and by increasing sensations of satiety, thereby reducing caloric intake and potentiating weight loss. There appears to be at least three distinct receptor complexes that bind with high affinity to amylin. All three complexes contain the calcitonin receptor at the core, plus one of three Receptor activity-modifying proteins, RAMP1, RAMP2, or RAMP3.
n3:packager
n18:271B6283-363D-11E5-9242-09173F13E4C5 n18:271B6289-363D-11E5-9242-09173F13E4C5 n18:271B6287-363D-11E5-9242-09173F13E4C5 n18:271B6288-363D-11E5-9242-09173F13E4C5 n18:271B6285-363D-11E5-9242-09173F13E4C5 n18:271B6286-363D-11E5-9242-09173F13E4C5 n18:271B6284-363D-11E5-9242-09173F13E4C5
n3:patent
n7:6610824 n7:5686411
n3:routeOfElimination
Pramlintide is metabolized primarily by the kidneys.
n3:proteinBinding
Pramlintide does not extensively bind to blood cells or albumin (approximately 40% of the drug is unbound in plasma).
n3:salt
n3:synthesisReference
Andreas Brunner, Oleg Werbitzky, Stephane Varray, Francesca Quattrini, Holger Hermann, Andrew Strong, Fernando Albericio, Judit Tulla-Puche, Yesica Garcia Ramos, "PROCESS FOR THE PRODUCTION OF PRAMLINTIDE." U.S. Patent US20100249370, issued September 30, 2010.
foaf:page
n5:symlin.htm n6:pramlintide.html
n3:Molecular-Formula
n21:271B6290-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n21:271B628F-363D-11E5-9242-09173F13E4C5
n14:hasATCCode
n15:A10BX05
n3:absorption
The absolute bioavailability of a single subcutaneous dose of pramlintide is approximately 30 to 40%.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
151126-32-8
n3:containedIn
n10:271B628C-363D-11E5-9242-09173F13E4C5 n10:271B628D-363D-11E5-9242-09173F13E4C5 n10:271B628A-363D-11E5-9242-09173F13E4C5 n10:271B628B-363D-11E5-9242-09173F13E4C5